Skip to main content
NewslettersWatchlist

Insmed Inc(INSM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low72.00
Day High74.03
Open:72.02
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
3 Small-Cap Stock ETFs Set to Surge if the Federal Reserve Cuts Rates
Motley Fool
A Russell 2000 Bull Market Is Coming: 1 Unstoppable Vanguard ETF to Buy Hand Over Fist
Motley Fool
1 Historically Cheap Vanguard Index Fund to Buy Before It Soars 40%, According to a Wall Street Analyst
Barchart
3 Top ETFs to Add Small-Cap Stock Exposure
Barchart
Mega-Cap Tech Stocks Climb and Boost the Broader Market
Barchart
Strength in Mega-Cap Tech Stocks Lifts the Broader Market
Barchart
Stocks See Support from a Rebound in Nvidia
Barchart
Stocks See Support from Chip Stocks But T-Note Yield Rises
Barchart
Stocks Mixed in TodayAfternoon Trade
Barchart
Stocks See Mild Pressure from Hawkish Fed Comments
The Globe and Mail
14 top U.S. equities to watch for price trend chasers
PR Newswire
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Why Shares of Insmed Are Soaring This Week
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Why Insmed Stock Is Soaring Today
BayStreet.ca
The Five Biotech Stocks Every Investor Should Know About
BayStreet.ca
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
PR Newswire
Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Profile

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.